[Surgical intramyocardial stem cell therapy for chronic ischemic heart failure].
Chronic ischemic heart disease patients are already being treated worldwide with bone marrow stem cells both in the context of clinical studies and in therapy trials. By combining this therapy with established revascularization procedures such as bypass surgery, a high level of patient safety can be achieved. To date, no stem cell-related cardiac complications following intramyocardial injection of bone marrow-derived stem cells during CABG (coronary artery bypass graft) surgery have been reported. The functional advantage conferred by surgical bone marrow stem cell therapy is a 7.2% increase in LVEF (left ventricular ejection fraction) compared to controls. Randomized placebo-controlled trials, like the German trial PERFECT, are needed to obtain a more evidence-based assessment of this therapy.
Kaminski
Alexander
A
Klinik für Herzchirurgie, Universität Rostock, Schillingallee 35, Rostock,Germany. alexander.kaminski@med.uni-rostock.de
Donndorf
Peter
P
Klopsch
Christian
C
Steinhoff
Gustav
G
D016026:Bone Marrow Transplantation / Q000379:methods*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D018849:Controlled Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006333:Heart Failure / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology / Q000601:surgery*; D017202:Myocardial Ischemia / Q000503:physiopathology / Q000601:surgery*; D013318:Stroke Volume / Q000502:physiology; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000503:physiopathology / Q000601:surgery; D016277:Ventricular Function, Left / Q000502:physiology